### Day 1: January 28

**IS01:** Satellite CME Symposium by Clinical Care Options: Advances in Antibody-Drug Conjugates for Treatment of Non-Small Cell Lung Cancer

**IS02:** Industry Symposium Sponsored by AstraZeneca: Evolving the Role of Immunotherapy in Lung Cancer ESSCLC and Unresectable Stage II NSCLC

**IS03:** Industry Symposium Sponsored by Daiichi-Sankyo: Antibody Drug Conjugates (ADC) as Therapeutic Options for Advanced NSCLC: Opportunities and Challenges

**IS04:** Industry Symposium Sponsored by Eli Lilly: Implementing Precision Oncology in the Clinic: Diagnostic Challenges and Best Practices

**IS05:** Industry Symposium Sponsored by Pfizer: Redefining Survival Expectations in Lung Cancer

**IS06:** Industry Symposium Sponsored by Novartis: Novel Frontiers in the Treatment of NSCLC

**IS07:** Industry Symposium Sponsored by Roche: Expert Perspectives on the Management of Lung Cancer

### Day 2: January 29

**IS08:** Industry Symposium Sponsored by Janssen: What the Future Holds for Advanced NSCLC Patients with Resistance to EGFR TKIs

**IS09:** Industry Symposium Sponsored by Bristol Myers Squibb: Thoracic Cancers, New Developments with IO

**IS10:** Industry Symposium Sponsored by Bristol Myers Squibb: The New WHO Biomarkers in Immunotherapy

**IS11:** Industry Symposium Sponsored by Boehringer Ingelheim: Advances in Diagnostics, Perioperative Developments and Novel Issues in Lung Cancer

### Day 3: January 30

**IS12:** Industry Symposium Sponsored by AstraZeneca: Evolving Treatment and Testing Paradigms in EGFR-mutated NSCLC: The MDT Perspective

**IS13:** Satellite CME Symposium by AEC Oncology: Hot Topics in the Management of Advanced Non-Small Cell Lung Cancer: Expert Insights on Recent Advances

**IS14:** Industry Symposium Sponsored by Amgen: Redefining Survival Expectations in Lung Cancer: Expert Insights on Recent Advances

**IS15:** Industry Symposium Sponsored by Pfizer: Choosing the Right Path: From Diagnostic to Treatment

**IS16:** Industry Symposium Sponsored by Janssen: Advancing Next Frontier of Innovation in Lung Cancer Therapies

**IS17:** Industry Symposium Sponsored by Novartis: On the Management of Biomarkers for Immune Therapies in NSCLC

**IS18:** Industry Symposium Sponsored by Roche: Expert Insights on the Management of Lung Cancer Therapies

### Day 4: January 31

**IS19:** Industry Symposium Sponsored by Boehringer Ingelheim: Advances in Diagnostics, Perioperative Developments and Novel Issues in Lung Cancer

**IS20:** Industry Symposium Sponsored by Pfizer: Redefining Survival Expectations in Lung Cancer: Expert Insights on Recent Advances

**IS21:** Industry Symposium Sponsored by Janssen: Advancing Next Frontier of Innovation in Lung Cancer Therapies

**IS22:** Industry Symposium Sponsored by Novartis: On the Management of Biomarkers for Immune Therapies in NSCLC

**IS23:** Industry Symposium Sponsored by Roche: Expert Insights on the Management of Lung Cancer Therapies

**IS24:** Industry Symposium Sponsored by Merck: Expert Insights on the Management of Lung Cancer Therapies

**IS25:** Industry Symposium Sponsored by AstraZeneca: Evolving Treatment and Testing Paradigms in EGFR-mutated NSCLC: The MDT Perspective

**IS26:** Industry Symposium Sponsored by Amgen: Redefining Survival Expectations in Lung Cancer: Expert Insights on Recent Advances

**IS27:** Industry Symposium Sponsored by Janssen: Advancing Next Frontier of Innovation in Lung Cancer Therapies

**IS28:** Industry Symposium Sponsored by Novartis: On the Management of Biomarkers for Immune Therapies in NSCLC

**IS29:** Industry Symposium Sponsored by Roche: Expert Insights on the Management of Lung Cancer Therapies

**IS30:** Industry Symposium Sponsored by Merck: Expert Insights on the Management of Lung Cancer Therapies

---

These programs are not sponsored or endorsed by IASLC and are not part of the official IASLC accredited program.